Oncology NEWS International March 2008 Vol. 17 No. 3

A Sneak Peek at 2025 ASCO From the GU Perspective

Shannon L. Puhalla, MD, delves into the clinical application, efficacy, and safety profiles of T-DXd and sacituzumab govitecan for patients with breast cancer.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD

61 Can the Use of Tumor Margin Markers for Intraoperative Specimen Radiographs Decrease the Rate of Margin Positivity During Breast Conservation Therapy?

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, highlight exciting trials in the genitourinary cancer space expected to be presented at 2025 ASCO.

Camila Ortega;Micah Brainerd;Christopher Mamone;Caroline Mangira;Andrew Fenton;Mary Murray

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Viviana Cortiana, MS4;Yan Leyfman, MD

May 12th 2025

Pembrolizumab Combo Extends PFS in Platinum-Resistant Ovarian Cancer

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.

Russ Conroy

Utility of the Diagnosis-Specific Graded Prognostic Assessment for Prognostication in Leptomeningeal Disease

Data from the KEYNOTE-B96 trial also show a significant overall survival improvement with pembrolizumab-based treatment in PD-L1–positive disease.

Meghana Kesireddy, MBBS;Rosalyn Marar, MD;Kaeli Samson, MA, MPH;Nicole A. Shonka, MD

Expanding Horizons and Gaining Insights on T-DXd and Sacituzumab in Breast Cancer

This retrospective study included 64 patients with LMD, with primary cancers represented in the diagnosis-specific Graded Prognostic Assessment (DS-GPA) at a single institution over 5 years.

Related Content

Ariana Pelosci

May 16th 2025

A Sneak Peek at 2025 ASCO From the GU Perspective

Shannon L. Puhalla, MD, delves into the clinical application, efficacy, and safety profiles of T-DXd and sacituzumab govitecan for patients with breast cancer.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD

61 Can the Use of Tumor Margin Markers for Intraoperative Specimen Radiographs Decrease the Rate of Margin Positivity During Breast Conservation Therapy?

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, highlight exciting trials in the genitourinary cancer space expected to be presented at 2025 ASCO.

Camila Ortega;Micah Brainerd;Christopher Mamone;Caroline Mangira;Andrew Fenton;Mary Murray

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Viviana Cortiana, MS4;Yan Leyfman, MD

May 12th 2025

Pembrolizumab Combo Extends PFS in Platinum-Resistant Ovarian Cancer

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.

Russ Conroy

Utility of the Diagnosis-Specific Graded Prognostic Assessment for Prognostication in Leptomeningeal Disease

Data from the KEYNOTE-B96 trial also show a significant overall survival improvement with pembrolizumab-based treatment in PD-L1–positive disease.

Meghana Kesireddy, MBBS;Rosalyn Marar, MD;Kaeli Samson, MA, MPH;Nicole A. Shonka, MD